Japan's Ministry of Health, Labour and Welfare has approved Sanofi's (EURONEXT: SAN, NASDAQ: SNY) subcutaneous formulation of Sarclisa (isatuximab) for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE